公司名稱： 無錫藥明康德新藥開發股份有限公司 呈交日期： 2025年6月3日 FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | A | | | 於香港聯交所上市 | | 否 | | | 證券代號 (如上市) | | 說明 | | 於上海證券交易所上市 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | ...

Group 1 - The core viewpoint of the article highlights the performance and valuation of WuXi AppTec, with a closing price of 63.51 yuan and a rolling PE ratio of 16.41 times, significantly lower than the industry average of 39.82 times [1][2] - As of the first quarter of 2025, a total of 387 institutions hold shares in WuXi AppTec, with 378 being funds, totaling 110,979.98 million shares and a market value of 74.712 billion yuan [1] - The company reported a revenue of 9.655 billion yuan for the first quarter of 2025, representing a year-on-year increase of 20.96%, and a net profit of 3.672 billion yuan, up 89.06% year-on-year, with a gross margin of 42.26% [1] Group 2 - WuXi AppTec's main business is providing integrated, end-to-end drug research and development services for the global pharmaceutical and life sciences industry, with key products in chemical, testing, and biological services [1] - In terms of market valuation, WuXi AppTec ranks 17th in the medical services industry, which has an average PE ratio of 39.82 times and a median of 46.56 times [1][2] - The company's total market capitalization stands at 183.416 billion yuan [1][2]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 無錫藥明康德新藥開發股份有限公司 呈交日期： 2025年5月30日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | | 普通股 | 股份類別 A | | | 於香港聯交所上市 | 否 | | | 證券代號 (如上市) | | | 說明 | 於上海證券交易所上市 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | | 事件 | ...

表格類別： 股票 狀態： 新提交 FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 公司名稱： 無錫藥明康德新藥開發股份有限公司 呈交日期： 2025年5月30日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | | 普通股 | 股份類別 A | | | 於香港聯交所上市 | 否 | | | 證券代號 (如上市) | | | 說明 | 於上海證券交易所上市 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | | 事件 | ...

Market Overview - The A-share market experienced an overall increase on May 29, with the Shanghai Composite Index closing at 3363.45 points, up 0.7%, the Shenzhen Component Index at 10127.2 points, up 1.24%, and the ChiNext Index at 2012.55 points, up 1.37%. The North Star 50 Index rose by 2.73%. Total trading volume reached 12136.01 billion yuan, an increase of 1795.28 billion yuan compared to the previous trading day [1]. Capital Flow - The net inflow of main funds in the A-share market was 74.33 billion yuan, with an opening net outflow of 19.58 billion yuan and a closing net inflow of 23.89 billion yuan [2]. - The net inflow for the CSI 300 was 12.91 billion yuan, while the ChiNext saw a net inflow of 42.65 billion yuan, and the STAR Market experienced a net outflow of 17.3 billion yuan [4]. Sector Performance - Among the 23 sectors, the computer industry led with a net inflow of 191.73 billion yuan, followed by the electronics sector with 124.39 billion yuan, and the pharmaceutical and biological sector with 112.04 billion yuan. The non-bank financial sector saw a net inflow of 47.51 billion yuan, while the communication sector had 34.87 billion yuan [6][7]. - The sectors with the largest net outflows included food and beverage with -21.56 billion yuan, basic chemicals with -12.02 billion yuan, and banking with -8.89 billion yuan [7]. Individual Stock Activity - The stock with the highest net inflow was Shanzhi Gaoke, with 7.11 billion yuan [8]. - Institutional investors showed significant interest in several stocks, with Wangzi New Materials receiving a net buy of 41.11 million yuan, and Sifang Precision receiving 36.17 million yuan [11][12]. Institutional Focus - Recent institutional ratings highlighted several stocks, including Huichuan Technology with a target price of 73.00 yuan, indicating an upside potential of 8.83%, and Longying Precision with a target price of 24.70 yuan, suggesting a 19.73% upside [14].

Group 1 - The Hong Kong biopharmaceutical sector experienced a collective rise, with WuXi Biologics (02269.HK) and Junshi Biosciences (01877.HK) leading the gains, both increasing over 9% [1] - Other companies such as WuXi AppTec (02359.HK), Kanglong Chemical (300759.HK), Kelun Pharmaceutical (06821.HK), and Tigermed (03347.HK) also saw increases of 4%-5% [1] Group 2 - A significant ruling by the U.S. International Trade Court on May 28 declared the "day of liberation" tariff policy from the Trump administration unconstitutional, reducing policy uncertainty for Chinese pharmaceutical companies looking to expand overseas [3] - The ruling emphasized that the U.S. Constitution grants Congress exclusive power to regulate trade, limiting presidential authority in economic security matters [3] Group 3 - The first quarter of 2025 saw a surge in License-out transactions, totaling 41 deals worth approximately $36.93 billion, nearing the total for the entire year of 2023 [3] - Notable transactions included 3SBio's $12.5 billion upfront payment plus up to $4.8 billion in milestone payments to Pfizer for a PD-1/VEGF dual antibody drug [3] Group 4 - The upcoming ASCO annual meeting in Chicago is expected to showcase the international competitiveness of Chinese innovative drugs, with 71 studies from Chinese companies selected for oral presentations [4] - Key clinical data will be released by several prominent companies, including Innovent Biologics and China Biologic Products, which may reshape treatment standards for non-small cell lung cancer [4][5] Group 5 - The progress of ADC drugs developed by partners of WuXi Biologics and collaborations between Kelun Pharmaceutical and Merck is also attracting attention [5] - The increasing quantity and quality of results presented by Chinese pharmaceutical companies at top academic platforms like ASCO indicate a recognized research and development capability in oncology [5]

教育股也普遍上扬。其中，中教控股（00839.HK）涨8.7%，新东方-S（09901.HK）涨4.32%,思考乐教 育（01769.HK）涨2.56%,卓越教育集团（03978.HK）涨2.74%。 节假日概念股、体育用品、奢侈品股、香港零售股等消费股走高。美团-W（03690.HK）涨6.62%，消 息面，美团闪购618发布了酒品类首日战报，自5月28日启动以来的24小时内，酒类整体成交额相比增长 超18倍。同程旅行（00780.HK）涨4.34%，携程集团-S（09961.HK）涨3.51%，安踏体育（02020.HK） 涨4.18%，361度（01361.HK）涨3.49%。 稳定币概念板块午后爆发，其中，连连数字（02598.HK）飙升44.86%，众安在线（06060.HK）大涨 31.56%。消息面，美国副总统万斯5月28日表示，本届政府不认为稳定币会威胁美元的完整性。恰恰相 反，将其视为美国经济实力的倍增器。此外，近期香港立法会三读通过的《稳定币条例草案》。今年年 底前，合规的香港稳定币有望正式落地。 短视频概念、明星科网股等均表现活跃。快手-W（01024.HK）涨4.94%，京东集团-SW ...

呈交日期： 2025年5月29日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | A | | | 於香港聯交所上市 | 否 | | | 證券代號 (如上市) | | 說明 | | 於上海證券交易所上市 | | | | | | A. 已發行股份或庫存股份變動 | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | | 事件 | | | 佔有關事件前的現有已發 | | | 每股發行/出售價 (註4) | 已發行股份總數 | | | | 已發行股份（不包括庫存股份）數 目 | | 行股份（不包括庫存股 份）數目百分比 (註3) | | 庫存股份數目 | | ...

如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 A | | | 於香港聯交所上市 | 否 | | | 證券代號 (如上市) | | 說明 | 於上海證券交易所上市 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | 佔有關事件前的現有已發 行股份（不包括庫存股 份）數目百分比 (註3) | | 庫存股份數目 | 每股發行/出售價 (註4) | 已發行股份總數 | | 於下列日期開始時的結存(註1) | 2025年5月28日 | ...

Group 1 - The innovative drug sector is experiencing multiple favorable developments, with the Guotai Innovative Drug ETF (517110) leading the market and showing strong performance [1] - The ASCO annual meeting, a major platform for biopharmaceutical companies to present clinical research results, will take place from May 30 to June 3, 2025, in Chicago, showcasing significant clinical data from domestic innovative drug companies [1] - The inclusion of multiple domestic innovative drug research projects in the ASCO conference reflects the vigorous state of domestic pharmaceutical R&D and the progress made in cancer treatment [1] Group 2 - The Chinese innovative drug industry is rapidly reshaping the international pharmaceutical market, with leading domestic companies expected to achieve record high revenues and net profits in 2024 [2] - As of now, the total transaction amount for domestic innovative drugs reaching overseas has reached $45.5 billion, with upfront payments totaling $2.2 billion, indicating a strong growth trajectory [2] - The retail market for prescription drugs continues to grow steadily, with biological products and innovative drugs being the main drivers, highlighting the increasing penetration of innovative drugs in the market [2] Group 3 - The Chinese innovative drug industry is transitioning from a phase of capital bubble to a stage of genuine achievements, gaining recognition from multinational corporations [3] - The demand for pharmaceuticals is increasing due to rising health awareness and an aging population, creating opportunities for various pharmaceutical sectors [3] - The Guotai Innovative Drug ETF (517110) provides a way to invest in leading stocks within the innovative drug sector, capitalizing on the rapid industry growth [3]